Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENTPD1 | P49961 | 3/20 | 0.65 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.58 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.58 |
| ▸ | P2RY1 | P47900 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6825629 | 0.97 | ENTPD1 (0.63) | ENTPD1TRPM2RNASELP2RY1 | |
| SCHEMBL6827694 | 0.90 | ENTPD1 (0.68) | ENTPD1TRPM2P2RY1 | |
| SCHEMBL3021626 | 0.90 | ENTPD1 (0.67) | ENTPD1TRPM2RNASELP2RY1 | |
| SCHEMBL6894217 | 0.89 | ENTPD1 (0.66) | ENTPD1TRPM2RNASELP2RY1 | |
| SCHEMBL7699161 | 0.89 | ENTPD1 (0.66) | ENTPD1TRPM2RNASELP2RY1 | |
| SCHEMBL6827710 | 0.89 | ENTPD1 (0.70) | ENTPD1TRPM2P2RY1 | |
| SCHEMBL636536 | 0.84 | ENTPD1 (0.75) | ENTPD1TRPM2P2RY1 | |
| SCHEMBL636535 | 0.84 | ENTPD1 (0.75) | ENTPD1TRPM2P2RY1 | |
| SCHEMBL21283084 | 0.83 | ENTPD1 (0.77) | ENTPD1TRPM2RNASELP2RY1 | |
| SCHEMBL16805436 | 0.83 | ENTPD1 (0.77) | ENTPD1TRPM2RNASELP2RY1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210386829-A1 | COMPOSITIONS AND METHODS FOR MODULATING CGRP SIGNALING TO REGULATE INNATE LYMPHOID CELL INFLAMMATORY RESPONSES | HOWARD HUGHES MEDICAL INSTITUTE | 2021-12-16 | — | — | US | claimed |
| US-20210130438-A1 | PAN-CANCER T CELL EXHAUSTION GENES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2021-05-06 | — | — | US | claimed |
| US-20220002416-A1 | COMPOSITIONS AND METHODS FOR MODULATING CANCER IMMUNE FITNESS | UNIV COLUMBIA (US) | 2022-01-06 | — | — | US | disclosed |
| WO-2021263247-A2 | COMPOSITIONS AND METHODS FOR MODULATING CANCER IMMUNE FITNESS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2021-12-30 | — | — | WO | disclosed |
| US-20210386829-A1 | COMPOSITIONS AND METHODS FOR MODULATING CGRP SIGNALING TO REGULATE INNATE LYMPHOID CELL INFLAMMATORY RESPONSES | HOWARD HUGHES MEDICAL INSTITUTE | 2021-12-16 | — | — | US | disclosed |
| US-20210130438-A1 | PAN-CANCER T CELL EXHAUSTION GENES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2021-05-06 | — | — | US | disclosed |
| US-10927410-B2 | Compositions and methods for identification, assessment, prevention, and treatment of T-cell exhaustion using CD39 biomarkers and modulators | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-02-23 | — | — | US | disclosed |
| EP-3207063-B1 | METHODS FOR IDENTIFICATION T-CELL EXHAUSTION USING CD39 BIOMARKERS AND MODULATORS | DANA FARBER CANCER INST INC (US) | 2020-12-02 | — | — | EP | disclosed |
| US-20200147210-A1 | METHODS AND COMPOSITIONS OF USE OF CD8+ TUMOR INFILTRATING LYMPHOCYTE SUBTYPES AND GENE SIGNATURES THEREOF | THE BROAD INSTITUTE, INC. | 2020-05-14 | — | — | US | disclosed |
| EP-3207063-A2 | COMPOSITIONS AND METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION, AND TREATMENT OF T-CELL EXHAUSTION USING CD39 BIOMARKERS AND MODULATORS | Dana-Farber Cancer Institute, Inc. (US) | 2017-08-23 | — | — | EP | disclosed |
| US-20170233808-A1 | COMPOSITIONS AND METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION, AND TREATMENT OF T-CELL EXHAUSTION USING CD39 BIOMARKERS AND MODULATORS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2017-08-17 | — | — | US | disclosed |
| WO-2016061456-A9 | COMPOSITIONS AND METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION, AND TREATMENT OF T-CELL EXHAUSTION USING CD39 BIOMARKERS AND MODULATORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-11-17 | — | — | WO | disclosed |
| WO-2016061456-A2 | COMPOSITIONS AND METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION, AND TREATMENT OF T-CELL EXHAUSTION USING CD39 BIOMARKERS AND MODULATORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-04-21 | — | — | WO | disclosed |
| EP-2019834-B1 | ECTONUCLEOTIDASE INHIBITORS | UNIV BONN (DE) | 2014-07-09 | — | — | EP | disclosed |
| US-20100204182-A1 | ECTONUCLEOTIDASE INHIBITORS | RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITAT BONN (DE) | 2010-08-12 | — | — | US | disclosed |
| EP-1860113-A1 | Ectonucleotidase inhibitors | Rheinische Friedrich-Wilhelms-Universität Bonn (DE) | 2007-11-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204182-A1 | ECTONUCLEOTIDASE INHIBITORS | NT5E, NT5C2, ENTPD1 | ENTPD1 3/4885TRPM2 831/4885RNASEL 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.